Research programme - cancer therapeutics - Abveris/Immunitas Therapeutics
Latest Information Update: 05 Feb 2021
At a glance
- Originator Abveris; Immunitas Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer